New Zealand Chapter

ISPOR (NZ) WORKSHOP SERIES

Thursday, 17 October 2019, 9:00 am-3:30 pm
Massey University, Wellington

PERSPECTIVES ON HEALTH ECONOMICS IN NEW ZEALAND

PROGRAMME

9:00 am  Welcome: Trudy Sullivan, President, ISPOR (NZ)

9:10 am  KEYNOTE SPEAKER: Maarten J. IJzerman

Using Real-World Data for Precision Medicine: Where do Patient Preferences play a role?

We are very pleased to welcome Professor Maarten J. IJzerman as the keynote speaker for the workshop. Professor IJzerman is the VCCC professor and head of Cancer Health Services Research in the University of Melbourne, Centre for Cancer Research and Centre for Health Policy. He also holds a fractional appointment as a professor of Health Technology Assessment in the University of Twente in the Netherlands. He is leading a global research program focused on the health economics and service delivery of precision medicine, in particular oncology. The research program includes the use of real-world (linked) data for health services research, the use of decision modelling methods for biomarker development, patient-preferences research and dynamic treatment sequencing.

His team is internationally recognised for his work on early-stage Health Technology Assessment supporting the translation of research findings to health services. He is a co-investigator in several large research programs in the European Union, Canada and Australia with a main interest in understanding patient value of new biomarker and treatments across clinical pathways. He is a member of several professional societies and a global leader in the International Society for Pharmacoeconomics and Outcomes Research (ISPOR).

Maarten has had leadership roles as the CEO of a rehabilitation research institute (2000-2007), director and vice-dean for Health & Biomedical Technology (2014-2017) in the University of Twente and as a board member in two hospitals (Máxima Medisch Centrum and Radiotherapiegroep) in the Netherlands responsible for innovation and technology (2011-2019). In Australia, he is a member of the Biogrid business advisory board and the Melbourne Academic Centre for Health (MACH) Health Services and Clinical Informatics Committee. Maarten is co-chairing the VCCC data-driven cancer health services research program.

10:00 am  Morning tea
### Speakers

**Sarah Hogan** is a health economist by training and has worked in health policy and health technology assessment within the Canadian, Australian and New Zealand public health systems. She currently leads the Analytics Team within Strategy, Innovation and Performance at Capital and Coast DHB.

**Carsten Schousboe** is a Senior Health Economist at PHARMAC, his specific focus is on health technology and pharmaceutical cost modelling. He is currently working towards a PhD with Otago University focusing on the measurement of health outcomes in cost effectiveness analysis.

**Michaela Lion** is the Head of Market Access and External Affairs at AbbVie New Zealand. She is responsible for the reimbursement of medicines including funding applications and price negotiations with PHARMAC. Michaela has a Masters in Economics from the University of Otago and spent 6 years working in the pharmaceutical industry in the UK before returning to New Zealand 4 years ago.

### Programme Continued

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:20 am</td>
<td><em>Sarah Hogan</em></td>
<td>Sarah will describe CCDHB’s aspirations to shift the evidence base for DHB decision-making from descriptive activity-based analytics to future-focused analytics with person-centred frameworks, and the opportunities and challenges for health economics.</td>
</tr>
<tr>
<td>10:50 am</td>
<td><em>Carsten Schousboe</em></td>
<td>Throughout the past 25 years, PHARMAC has had a significant impact on pharmaceutical spending patterns in New Zealand. This presentation explores how PHARMAC makes new investment decisions. A focus of this presentation will be on how health-related quality of life data is accessed and evaluated.</td>
</tr>
<tr>
<td>11:20 am</td>
<td><em>Michaela Lion</em></td>
<td>This presentation will highlight the opportunities and challenges for pharmaceutical companies in achieving and maintaining funded access to medicines in New Zealand. A recent patient-led movement has resulted in some changes to the PHARMAC model but is there more to be done?</td>
</tr>
<tr>
<td>11:50 am</td>
<td><em>TBC</em></td>
<td>We are confirming a fourth speaker for this session to present on the role of health economics in informing government policy and priorities within the health sector.</td>
</tr>
<tr>
<td>12:20 pm</td>
<td>Lunch</td>
<td></td>
</tr>
</tbody>
</table>
1:00 pm  **Panel discussion**  
The presenters from the morning session will come together for a moderated panel discussion on the various uses of health economics to inform health policy and resource allocation in the healthcare system.

2:00 pm  **Richard Milne**  
Multiple myeloma is a type of cancer that develops from plasma cells in the bone marrow. This presentation will describe the burden of myeloma in New Zealand, including its recent history, clinical outcomes and cost in the era of modern biologicals.

2:30 pm  **Carlo Marra**  
The aim for this study was to measure the relative importance of values considered most relevant in informing drug funding decisions in a national representative sample of the New Zealand public. In addition, this study aimed to determine attitudes towards funding drugs for common and rare diseases.

3:00 pm  **Trudy Sullivan**  
The EQ-5D is a commonly-used instrument for measuring health-related quality of life, an essential component in most health economic evaluations and much health outcome research. Recently, an EQ-5D-5L value set (comprised from 2468 personal value sets) has been created for New Zealand using a tool not used in this area before.

3:30 pm  **Refreshments and networking**

---

**Speakers**

- **Panellists:**
  - Maarten J. Ijzerman
  - Sarah Hogan
  - Carsten Schousboe
  - Michaela Lion
  - TBC

**Richard Milne** is a private consultant in health technology assessment and Associate Professor in the School of Pharmacy at the University of Auckland. Richard was founding Editor of PharmacoEconomics, a founding member of ISPOR NZ, and its first President.

**Carlo Marra** is a Professor and Dean of the School of Pharmacy at the University of Auckland. He has been active in conducting economic analyses, choice experiments and costing studies throughout portions of the last three decades.

**Trudy Sullivan** is a health economist and senior lecturer at the University of Otago. She is currently leading a project to validate a newly-created EQ-5D-5L value set for NZ. As part of this project she will be exploring the preferences of New Zealanders in regard to health-related quality of life.
REGISTRATION FORM

To register for the meeting please fill in the registration form below and email to:

ispornewzealand@gmail.com

Name: __________________________________________________________

Company or Institution: ___________________________________________

Email address: __________________________________________________

Phone contact: __________________________________________________

Cost:  

- $75 ISPOR (NZ) member / ISPOR (international) member
- $125 Non-member

Combined ISPOR (NZ) annual membership and conference:

- $75 student (no charge for students to join)
- $125 if ISPOR (international) membership
- $150 if neither student nor ISPOR (international) member

Require invoice:  □ Yes  □ No

Payment by electronic credit to:  ISPOR NZ Chapter, Acc no. 03-1702-0365754-00

Please ensure your name is referenced when making payment.

Signature: __________________________________________________________

- I am happy for my details to be retained on file for further contact
- Please do not retain a record of my contact details